Neos Therapeutics, Inc. (NEOS)
Stock Price:
$0.735 USD
0.015 (2.10%)
Updated Aug 10, 2020 9:49 AM EDT - Market open
Key Info
| Market Cap |
36.57M |
| Revenue (ttm) |
64.51M |
| Net Income (ttm) |
-17.25M |
| Shares Out |
49.75M |
| EPS (ttm) |
-0.35 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$0.735 |
| Previous Close |
$0.720 |
| Change ($) |
0.015 |
| Change (%) |
2.10% |
| Day's Open |
0.730 |
| Day's Range |
0.730 - 0.740 |
| Day's Volume |
81,348 |
| 52-Week Range |
0.600 - 2.150 |
More Stats
| Market Cap |
36.57M |
| Enterprise Value |
62.02M |
| Earnings Date (est) |
Aug 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
49.75M |
| Float |
37.41M |
| EPS (basic) |
-0.35 |
| EPS (diluted) |
-0.35 |
| FCF / Share |
-0.14 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.18M |
| Short Ratio |
6.65 |
| Short % of Float |
2.37% |
| Beta |
1.25 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
0.57 |
| PB Ratio |
n/a |
| Revenue |
64.51M |
| Operating Income |
-10.48M |
| Net Income |
-17.25M |
| Free Cash Flow |
-6.76M |
| Net Cash |
-25.45M |
| Net Cash / Share |
-0.51 |
| Gross Margin |
61.27% |
| Operating Margin |
-16.25% |
| Profit Margin |
-26.70% |
| FCF Margin |
-10.48% |
| ROA |
-6.85% |
| ROE |
-1,971.08% |
| ROIC |
-21.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$7.00*
(852.25% upside)
Low
2.00
Current: $0.735
High
10.00
Target: 7.00
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 64.65 | 49.99 | 27.13 | 10.03 | 3.79 | 0.76 | 1.04 |
| Revenue Growth | 29.33% | 84.24% | 170.43% | 164.58% | 400.26% | -27.39% | - |
| Gross Profit | 39.53 | 23.06 | 13.10 | -1.70 | -2.14 | -2.63 | -1.49 |
| Operating Income | -10.42 | -43.50 | -56.54 | -75.82 | -26.58 | -18.47 | -17.09 |
| Net Income | -16.90 | -51.68 | -65.77 | -82.75 | -30.78 | -20.85 | -15.63 |
| Shares Outstanding | 49.72 | 32.29 | 24.75 | 16.05 | 7.58 | 0.88 | 0.79 |
| Earnings Per Share | -0.34 | -1.60 | -2.66 | -5.16 | -4.38 | -27.56 | -28.45 |
| Operating Cash Flow | -10.78 | -41.44 | -53.26 | -70.65 | -25.87 | -17.39 | -14.96 |
| Capital Expenditures | -1.09 | -1.36 | -2.50 | -3.55 | -1.02 | -0.34 | -2.02 |
| Free Cash Flow | -11.87 | -42.80 | -55.76 | -74.20 | -26.89 | -17.73 | -16.97 |
| Cash & Equivalents | 24.89 | 46.48 | 50.42 | 39.78 | 90.76 | 16.34 | 0.00 |
| Total Debt | 48.87 | 51.77 | 59.83 | 63.52 | 34.24 | 24.77 | - |
| Net Cash / Debt | -23.98 | -5.30 | -9.42 | -23.74 | 56.52 | -8.43 | 0.00 |
| Assets | 90.87 | 111 | 104 | 80.14 | 123 | 45.23 | - |
| Liabilities | 97.00 | 104 | 95.16 | 81.69 | 44.14 | 124 | - |
| Book Value | -6.13 | 7.85 | 8.95 | -1.55 | 78.37 | -78.78 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Neos Therapeutics, Inc. |
| Country |
United States |
| Employees |
213 |
| CEO |
Gerald W. McLaughlin |
Stock Information
| Ticker Symbol |
NEOS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: NEOS |
| IPO Date |
July 23, 2015 |
Description
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for treating of ADHD; Adzenys ER amphetamine to treat ADHD; and generic Tussionex hydrocodone and chlorpheniramine for cough and upper respiratory symptoms of a cold. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.